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Abstract
The synthesis, secretion and clearance of von Willebrand factor (VWF) are regulated by genetic variations in coding and
promoter regions of the VWF gene. We have previously identified 19 single nucleotide polymorphisms (SNPs), primarily
in introns that are associated with VWF antigen levels in subjects of European descent. In this study, we conducted race
by gender analyses to compare the association of VWF SNPs with VWF antigen among 10,434 healthy Americans of
European (EA) or African (AA) descent from the Atherosclerosis Risk in Communities (ARIC) study. Among 75 SNPs
analyzed, 13 and 10 SNPs were associated with VWF antigen levels in EA male and EA female subjects, respectively.
However, only one SNP (RS1063857) was significantly associated with VWF antigen in AA females and none was in AA
males. Haplotype analysis of the ARIC samples and studying racial diversities in the VWF gene from the 1000 genomes
database suggest a greater degree of variations in the VWF gene in AA subjects as compared to EA subjects. Together,
these data suggest potential race and gender divergence in regulating VWF expression by genetic variations.
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Introduction
von Willebrand factor (VWF) is a multimeric glycoprotein
ligand essential in initiating hemostasis at sites of vessel injury [1].
It can also promote thrombosis by mediating platelet adhesion to
activated endothelium and/or subendothelium at sites of ruptured
atherosclerotic plaques, or aggregating platelets under pathological
high shear stress found at sites of arterial stenosis [2;3]. An
elevated plasma level of VWF is an independent risk factor for
coronary heart disease (CHD), ischemic stroke, and peripheral
artery disease [4;5], whereas low VWF antigen and activity could
result in bleeding associated with von Willebrand disease (VWD)
[6].
Plasma VWF antigen levels vary significantly among healthy
individuals [7;8]. Both environmental and genetic factors
contribute to this variation. The former includes conditions
known to stimulate endothelial cells to secret VWF [9;10],
whereas the latter plays a dominant role in determining a baseline
level of circulating VWF [11;12]. ABO blood types greatly
influence the baseline level of plasma VWF. Individuals with
blood type O have a lower level of circulating VWF, resulting
from an accelerated clearance of VWF from the circulation [13].
Genetic variations in the promoter and coding regions of the
VWF gene are known to affect VWF levels [14;15]. We have
previously identified intronic single nucleotide polymorphisms
(SNPs) and their haplotypes that are associated with plasma VWF
levels in 7,856 subjects of European descent (EA) from the
Atherosclerosis Risk in Communities (ARIC) cohort [16]. We
have also detected a significant ethnic diversity of variations in
the VWF gene among subjects included in the 1000 genomes
database [17]. In this study, we further examined potential race
and gender differences in this association between VWF antigen
and VWF gene variations. This study is important because AA
subjects often have a higher level of circulating VWF antigen
[7;8;18]. Recent studies by Bellissimo D. B., et al [19] and by us
[17] show that some ‘‘mutations’’ that were originally associated
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with VWD in Caucasians are found in 10–20% of African
subjects without evidence of clinical bleeding, even though some
of these ‘‘VWD mutants’’ are dose-dependently associated with
VWF levels in apparently healthy AA subjects [20]. Together,
these data suggest that 1) the association between variations in the
VWF gene and plasma levels of VWF antigen may vary by race
and 2) this racial diversity may impact on how genetic variations
influence VWF synthesis, secretion and clearance. In this study,
we further examined the racial diversity in this association
between VWF antigen and VWF gene variations between the EA
and AA subjects from the ARIC cohort.
Methods
The Atherosclerosis Risk in Communities (ARIC, http://
www.cscc.unc.edu/aric/) is a prospective cohort study designed
to assess subclinical atherosclerosis and clinical atherosclerotic
events and cardiovascular risk factors [21]. Among 15,792
ARIC participants, 10,434 were included in this study after
exclusion of subjects lacking data on 1) VWF antigen (n = 280),
2) VWF SNPs (n = 3,032), or 3) ABO genotypes (n = 1,898).
The study also excluded non-EA and non-AA individuals (n =
Table 1. Demographic and Plasma VWF for 10,434 ARIC
Participants by Race.
Characteristics Race
AA EA P value
Subject included N (%) 2,378 (22.8) 8,056 (77.2)
Gender F 1,505 4,286 , 0.001
M 873 3770
BMI Mean (s.d) 30.12 (6.37) 27.01 (4.67) , 0.001
Diabetes N (%) 452 (19.3) 726 (9.1) , 0.001
Hypertension N (%) 1,308 (55.0) 2,256 (27.8) , 0.001
History of smoking* N (%) 1,260 (53.1) 4,818 (59.8) , 0.001
VWF [mean (s.d)] F 128.15 (54.42) 108.44 (41.10) , 0.001
M 122.74 (51.16) 111.34 (42.36) , 0.001
*include current and former smokers.
doi:10.1371/journal.pone.0084810.t001
Table 2. SNPs Associated with Plasma VWF Levels Analyzed for Race-by-Gender.
SNP Race by Sex Mean ± S.E. (Genotype frequency %) P value#
AA AB BB
RS1063857 (Exon 18) EA-F 104.860.9 (41%) 109.860.8 (46%) 115.361.6 (13%) ,.0001
EA-M 106.561.0 (40%) 113.060.9 (47%) 119.761.7 (13%) ,.0001
AA-F 117.763.2 (16%) 126.661.8 (50%) 136.062.2 (33%) ,.0001
AA-M 113.564.2 (16%) 12162.3 (50%) 128.362.7 (35%) 0.0076
RS216315 (Intron 22) EA-F 91.465.7 (1%) 100.761.4 (16%) 110.160.6 (83%) ,.0001
EA-M 97.966.4 (1%) 105.961.6 (15%) 112.37460.7 (84%) 0.0001
AA-F 123.665.1 (7%) * 128.761.3 (93%) 0.3382
AA-M 117.965.9 (7%) * 122.961.7 (93%) 0.4186
RS11610629 (Intron 22) EA-F 106.560.7 (56%) 110.360.9 (38%) 113.762.4 (6%) 0.0004
EA-M 108.960.9 (55%) 113.361.0 (39%) 118.262.6 (6%) ,.0001
AA-F 124.961.8 (54%) 131.162.1 (39%) 134.765.2 (7%) 0.0362
AA-M 119.562.3 (49%) 127.562.5 (43%) 114.866.1 (8%) 0.0277
RS216318 (Intron 21) EA-F 92.165.5 (1%) 100.761.4 (16%) 110.160.6 (83%) ,.0001
EA-M 97.966.4 (1%) 105.861.6 (15%) 112.460.7 (84%) ,.0001
AA-F 120.564.6 (8%) * 129.061.4 (92%) 0.0788
AA-M 117.965.8 (8%) * 123.061.7 (92%) 0.4004
RS216295 (Intron 17) EA-F 110.160.6 (82%) 101.661.4 (17%) 92.965.5 (1%) ,.0001
EA-M 112.360.7 (83%) 106.461.6 (16%) 91.766.8 (1%) ,.0001
AA-F 130.561.6 (66%) 125.362.4 (31%) 110.867.8 (3%) 0.0153
AA-M 123.561.9 (68%) 120.263.1 (29%) 124.968.9 (3%) 0.6384
RS216298 (Intron 16) EA-F 94.865.4 (1%) 101.261.4 (17%) 110.160.6 (82%) ,.0001
EA-M 95.166.2 (1%) 106.061.6 (16%) 112. 560.7 (83%) ,.0001
AA-F 113.068.1 (3%) 124.962.5 (26%) 130.161.5 (71%) 0.0351
AA-M 120.269.2 (3%) 120.763.3 (25%) 123.361.9 (72%) 0.7643
RS216299 (Intron 16) EA-F 96.365.0 (1%) 101.561.4 (17%) 110.060.6 (82%) ,.0001
EA-M 95.565.9 (1%) 106.261.6 (16%) 112.460.7 (83%) ,.0001
AA-F 112.067.9 (3%) 125.062.5 (26%) 130.261.5 (71%) 0.0242
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48) and those who did not consent to DNA use (n = 100).
Covariates included ABO genotypes (O vs. non-O), age, gender,
body mass index (BMI), hypertension, diabetes, and smoking
status, all of which are known to affect VWF antigen levels.
VWF measurements, SNP genotyping, haplotype construction,
and data analyses were previously described [16]. A polyclonal
VWF antibody was used to detect VWF antigen in plasma
samples, but if this antibody binds VWF multimers from EA and
AA subjects with an equal affinity has not been experimentally
determined.
The difference between EA and AA subjects in allele
frequencies of these VWF variants were further validated with
information from the April 2012 Integrated Variant Set release
of the 1000 Genomes Project (ftp://ftp.1000genomes.ebi.ac.uk/
vol1/ftp/release/20110521/ALL.wgs.phase1_release_v3.20101123.
snps_indels_sv.sites.vcf.gz). This database compiles information
on genomic variations among 1,092 subjects from 14 ethnicities
[25] and has been used to demonstrate a significant ethnic
allelic diversity of VWF SNPs among Africans, Americans of
European decent, Europeans and Asians [17].
Table 2. Cont.
SNP Race by Sex Mean ± S.E. (Genotype frequency %) P value#
AA AB BB
AA-M 121.168.8 (3%) 120.463.3 (25%) 123.361.9 (72%) 0.7458
RS12304995 (Intron 15) EA-F 105.560.9 (39%) 109.560.8 (48%) 113.361.6 (13%) ,.0001
EA-M 108.261.0 (39%) 112.360.9 (48%) 116.661.8 (13%) ,.0001
AA-F 126.163.0 (18%) 127.061.8 (51%) 132.562.4 (30%) 0.1279
AA-M 113.763.9 (17%) 126.262.3 (49%) 122.062.8 (34%) 0.0229
RS11609815 (Intron 24) EA-F 106.760.7 (56%) 110.460.9 (38%) 112.062.2 (7%) 0.0015
EA-M 108.960.9 (55%) 113.461.0 (38%) 118.562.4 (7%) ,.0001
AA-F 126.362.2 (36%) 129.761.9 (48%) 128.463.2 (16%) 0.4996
AA-M 121.862.8 (32%) 123.062.3 (50%) 122.863.9 (18%) 0.9463
RS11063995 (Intron 22) EA-F 111.962.2 (6%) 110.460.9 (38%) 106.760.7 (56%) 0.0016
EA-M 118.862.5 (7%) 113.261.0 (38%) 108.960.9 (55%) ,.0001
AA-F 128.363.3 (16%) 130.361.9 (48%) 126.562.2 (36%) 0.2735
AA-M 121.664 (17%) 123.662.3 (51%) 121.362.8 (31%) 0.7942
RS11612401 (Intron 22) EA-F 112.062.2 (6%) 110.460.9 (38%) 106.760.7 (56%) 0.0017
EA-M 118.662.4 (7%) 113.361.0 (38%) 108.960.9 (55%) ,.0001
AA-F 137.2610.5 (2%) 134.262.6 (24%) 126.261.5 (74%) 0.0232
AA-M 112.3610.1 (3%) 124.863 (29%) 12261.9 (69%) 0.4386
RS1800380 (Exon 22) EA-F 106.760.7 (56%) 110.360.9 (38%) 112.262.2 (6%) 0.0018
EA-M 109.060.9 (55%) 113.261.0 (38%) 118.562.4 (7%) ,.0001
AA-F 124.861.8 (50%) 131.762 (41%) 131.464.5 (9%) 0.0294
AA-M 119.262.4 (45%) 127.1162.4 (44%) 117.565.1 (11%) 0.0389
RS11609728 (Intron 21) EA-F 112.362.2 (6%) 110.460.9 (38%) 106.760.7 (56%) 0.0016
EA-M 118.562.4 (7%) 113.461.0 (38%) 108.960.9(56%) ,.0001
AA-F 129.663 (20%) * 128.061.4 (80%) 0.6181
AA-M 122.863.3 (24%) * 122.561.8 (76%) 0.9303
RS2239161 (Intron 15) EA-F 109.860.6 (79%) 103.661.3 (19%) 96.464.5 (2%) ,.0001
EA-M 112.460.7 (79%) 108.061.4 (20%) 100.565.2 (1%) 0.0028
AA-F 128.861.4 (88%) * 124.363.9 (11%) 0.2801
AA-M 123.561.7 (88%) * 112.064.6 (12%) 0.0207
RS2239160 (Intron 15) EA-F 96.264.5 (2%) 103.361.3 (19%) 109.860.6 (79%) ,.0001
EA-M 100.365.2 (1%) 107.561.4 (19%) 112.360.7 (79%) 0.0011
AA-F 116.2369.7 (2%) 129.262.7 (23%) 128.361.5 (75%) 0.4343
AA-M 121.163.1 (27%) * 123.161.9 (73%) 0.5746
# comparing mean VWF antigen by genotype* Combined with heterozygote due to limited number of subjects.
doi:10.1371/journal.pone.0084810.t002
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Results and Discussion
Characteristics of the 10,434 subjects are summarized in Table
1 and found to be consistent with our previous reports [16;22]. AA
subjects (N = 2,378) had significantly higher BMI and prevalences
of diabetes and hypertension, but a lower prevalence of smoking
compared to EA subjects (N = 8,056). The mean level of plasma
VWF varied significantly in race-by-gender groups. VWF levels
found in female subjects of this ARIC cohort are comparable to a
previous report on a different cohort by Millar C, at al [23]. ABO
blood groups (defined as O type vs. non-O type) explained 12.6%
of VWF variation when it was analyzed together with environ-
mental covariates (gender, age, race, BMI, hypertension, diabetes
and smoking status) in a linear regression model, slightly lower
than 15.2% for EA subjects [16].
We have previously identified 19 SNPs (17 intronic) in EA
subjects that were associated with VWF antigen levels after
adjustment for ABO and environmental covariates [16]. For
that study, we were unable to study AA subjects because ABO
genotype was imputed, a method that is not reliable for AA
subjects. ABO has since been genotyped in the ARIC cohort,
allowing us to analyze these 75 VWF SNPs for association with
VWF antigen in EA and AA subjects, separately (Table S1) and
to examine potential race and gender effects on the association.
Fifteen SNPs (20%) were associated with overall VWF antigen
levels after adjustments for environmental covariates and ABO
(Table 2). The genotype frequency differed significantly between
EA and AA subjects in 80% of these SNPs. Two of these SNPs
(RS1063857 and RS12304995) had a reversed genotype
frequency between EA and AA subjects. For the majority of
these 15 positive SNPs, the minor alleles were associated with a
higher level of VWF. Among these 15 positive SNPs, 13 and 10
reached statistical significance in EA males and EA females,
respectively, with 5 (38.5%) and 2 (20%) of them being
significant only in males and females, respectively.
In contrast, only one of these 15 positive SNPs (RS1063857)
was associated with VWF levels in AA females and none in AA
males (Table 2). RS1063857, which was associated with EA
males and females, is a synonymous SNP located in exon 18 of
the VWF gene. Nucleotide sequence in exon 18 encodes for the
D’ domain that is involved in VWF multimerization [24] and
binding FVIII [25]. This SNP also generated the strongest
association in our previous study of EA subjects [16] and was
associated with VWF antigen levels in a GWA study by the
Cohorts for Heart and Aging Research in Genomic Epidemi-
ology (CHARGE) consortium [26]. Together, these data suggest
potential race and gender diversities in allele frequencies for
these SNPs.
These race and gender diversities were further validated using
information provided in the 1000 Genomes Project. Among the 15
positive SNPs, 7 (53.3%) had allele frequencies of 1.9 – 9.6 fold
higher in Africans than in EA subjects and 1 (6.7%) was 2.7 fold
more common in EA subjects (Table 3). As expected, Americans of
European decent and European subjects had a highly comparable
level of allele frequencies for all 15 VWF SNPs. However, 6 SNPs
that differ most between Africans and EA were very rare in Asians
(. 100 fold less frequent).
In addition to individual SNPs, we also constructed haplotypes
that included rare VWF SNPs in order to identify SNPs that are
co-transmitted together. Using the fastPHASE 1.2 program, we
identified 10 and 13 major haplotype blocks that are in linkage
disequilibrium for EA and AA subjects, respectively (Figure 1).
SNPs in each LD haplotype varied significantly between EA and
AA subjects, indicating a highly diverse SNP co-aggregation
between EA and AA subjects.
In conclusion, we have identified VWF SNPs that appear to
be differentially associated with plasma levels of VWF antigen
between EA and AA subjects as well as between male and
female subjects. We did not detect a significant race-by-SNPs
interaction for several reasons. First, the numbers of AA
subjects were relatively small (N = 2,378) compared to EA
subjects (N = 8,056) because the difference in VWF antigen
associated with these intronic variations are expected to be
small. However, this small sample size is partially compensated
by higher allele frequencies in AA subjects for most of these
SNPs (Table 2 & Table 3). Second, the VWF gene is more
variable in AA subjects as suggested by their haplotypes (Figure
1). Finally, these VWF genetic variations may exert a smaller
influence on AA subjects because of their relative higher
baseline levels of VWF antigen. Covariates known to affect
VWF antigen levels (ABO, age, gender, body mass index,
hypertension, diabetes, and smoking status) were adjusted for
the data analyses, but other covariates may exist and are not
accounted for. These data need to be validated in larger cohorts
of mix ethnicities, but they, nevertheless, suggest that the
association between genetic and antigenic variations of VWF
could be influenced by race and gender. This notion of racial
divergence is consistent with recent reports that selective
‘‘mutations’’ previously associated with the bleeding disorder
VWD were detected at 10–21% of AA subjects without
documented bleeding [17;19]. The finding suggests that these
‘‘mutations’’ are unlikely to cause the disease. Our data,
therefore, suggest caution in associating a specific SNP with a
bleeding or thrombotic state without considering the impact of
race and gender.
Table 3. Allele Frequency of VWF SNP in Four Ethnic Groups
(%).
SNP Ref. allele Alt. allele African EA European Asian
RS1063857 A G 65 27 38 8
RS216315 A G 98 94 91 79
RS11610629 A C 27 22 25 0.17
RS216318 A C 98 93 91 79
RS216295 T C 85 9 91 77
RS216298 C T 87 91 91 77
RS216299 A G 87 91 91 77
RS12304995 C T 62 31 37 18
RS11609815 C G 41 22 25 0.17
RS11063995 T C 41 22 25 0.17
RS11612401 G C 11 2 25 0.17
RS1800380 C T 27 22 25 0.17
RS11609728 C A 7 19 25 0.17
RS2239161 G A 97 91 88 77
RS2239160 A G 86 9 88 77
doi:10.1371/journal.pone.0084810.t003
A Biracial Comparison of VWF Gene Polymorphisms
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Supporting Information
Table S1 Genotype frequencies of VWF SNPs by race
and gender.This table lists frequencies of all VWF SNPs
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Figure 1. VWF haplotypes. The haplotypes were constructed using the default setting that (1) ignores pairview comparisons of markers more than
500 kb apart, (2) excludes subjects with more than 50% of missing genotypes, (3) examines haplotypes found 1% or more in the population, (4)
removes markers with Hardy-Weinberg disequilibrium, and (5) uses R2 to define haplotype blocks.
doi:10.1371/journal.pone.0084810.g001
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